Global Radioligand Therapy Drugs Market Growth 2026-2032
The global Radioligand Therapy Drugs market size is predicted to grow from US$ 3087 million in 2025 to US$ 5316 million in 2032; it is expected to grow at a CAGR of 8.3% from 2026 to 2032.
In 2025, global Radioligand Therapy Drugs reached approximately 76.49 K Units, with an average global market price of around 41254 USD per Unit.
Radioligand Therapy (RLT) drugs are targeted radiopharmaceutical cancer medicines that pair a tumor-seeking “ligand” (targeting molecule) with a therapeutic radioactive isotope (radionuclide). After intravenous administration, the ligand binds to a specific target on (or in) cancer cells, and the radionuclide delivers cell-killing radiation locally, aiming to limit exposure to surrounding healthy tissue.
Radioligand therapy (RLT) drugs combine the precision of targeted medicine with the cell-killing power of radiation, delivering a therapeutic payload directly to tumors based on a molecular marker rather than just anatomy, which helps address several long-standing pain points in oncology: limited efficacy after multiple lines of treatment, high systemic toxicity from broadly acting drugs, and the need for better patient selection to avoid costly trial-and-error care. By pairing a targeting ligand with a therapeutic radioisotope, RLT can concentrate dose where disease is active—including small or disseminated lesions—while often remaining compatible with existing imaging workflows and multidisciplinary cancer care, making outcomes more predictable and enabling clearer treatment sequencing. Industry momentum is being driven by a convergence of factors: rapid growth in biomarker-guided oncology, rising unmet need in hard-to-treat metastatic disease, increasing confidence from real-world clinical adoption, and meaningful investment in isotope supply, manufacturing capacity, and specialized treatment infrastructure that reduces earlier bottlenecks. Looking ahead, the market potential is reinforced by a deepening pipeline across multiple tumor types and targets, next-generation isotopes and chemistries that may improve tumor penetration and durability, and expanding global capacity that can progressively normalize availability; as these elements mature, RLT is positioned to evolve from a niche option into a more routine modality that complements—and in some settings competes with—established systemic therapies, shaping a long runway for growth without relying on hype.
Radioligand Therapy Drugs' upstream raw materials mainly include therapeutic radionuclides, targeted ligands, and excipients. Typical suppliers include ITM, Curium, SHINE Technologies, and NRG. Downstream applications primarily involve the treatment of cancers such as prostate cancer, liver cancer, breast cancer, and lung cancer.
The production capacity of a single Radioligand Therapy Drugs production line is affected by the supply of radionuclides, synthesis efficiency, equipment configuration, and quality control standards. Significant differences exist between different drugs and production lines. Radioligand Therapy Drugs' gross profit margin ranges from 70% to 80%.
United States market for Radioligand Therapy Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Radioligand Therapy Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Radioligand Therapy Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Radioligand Therapy Drugs players cover Novartis, Bayer, Progenics (Lantheus), Acrotech Biopharma Inc, BMS, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Radioligand Therapy Drugs Industry Forecast” looks at past sales and reviews total world Radioligand Therapy Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Radioligand Therapy Drugs sales for 2026 through 2032. With Radioligand Therapy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radioligand Therapy Drugs industry.
This Insight Report provides a comprehensive analysis of the global Radioligand Therapy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Radioligand Therapy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Radioligand Therapy Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radioligand Therapy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radioligand Therapy Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Radioligand Therapy Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
In 2025, global Radioligand Therapy Drugs reached approximately 76.49 K Units, with an average global market price of around 41254 USD per Unit.
Radioligand Therapy (RLT) drugs are targeted radiopharmaceutical cancer medicines that pair a tumor-seeking “ligand” (targeting molecule) with a therapeutic radioactive isotope (radionuclide). After intravenous administration, the ligand binds to a specific target on (or in) cancer cells, and the radionuclide delivers cell-killing radiation locally, aiming to limit exposure to surrounding healthy tissue.
Radioligand therapy (RLT) drugs combine the precision of targeted medicine with the cell-killing power of radiation, delivering a therapeutic payload directly to tumors based on a molecular marker rather than just anatomy, which helps address several long-standing pain points in oncology: limited efficacy after multiple lines of treatment, high systemic toxicity from broadly acting drugs, and the need for better patient selection to avoid costly trial-and-error care. By pairing a targeting ligand with a therapeutic radioisotope, RLT can concentrate dose where disease is active—including small or disseminated lesions—while often remaining compatible with existing imaging workflows and multidisciplinary cancer care, making outcomes more predictable and enabling clearer treatment sequencing. Industry momentum is being driven by a convergence of factors: rapid growth in biomarker-guided oncology, rising unmet need in hard-to-treat metastatic disease, increasing confidence from real-world clinical adoption, and meaningful investment in isotope supply, manufacturing capacity, and specialized treatment infrastructure that reduces earlier bottlenecks. Looking ahead, the market potential is reinforced by a deepening pipeline across multiple tumor types and targets, next-generation isotopes and chemistries that may improve tumor penetration and durability, and expanding global capacity that can progressively normalize availability; as these elements mature, RLT is positioned to evolve from a niche option into a more routine modality that complements—and in some settings competes with—established systemic therapies, shaping a long runway for growth without relying on hype.
Radioligand Therapy Drugs' upstream raw materials mainly include therapeutic radionuclides, targeted ligands, and excipients. Typical suppliers include ITM, Curium, SHINE Technologies, and NRG. Downstream applications primarily involve the treatment of cancers such as prostate cancer, liver cancer, breast cancer, and lung cancer.
The production capacity of a single Radioligand Therapy Drugs production line is affected by the supply of radionuclides, synthesis efficiency, equipment configuration, and quality control standards. Significant differences exist between different drugs and production lines. Radioligand Therapy Drugs' gross profit margin ranges from 70% to 80%.
United States market for Radioligand Therapy Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Radioligand Therapy Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Radioligand Therapy Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Radioligand Therapy Drugs players cover Novartis, Bayer, Progenics (Lantheus), Acrotech Biopharma Inc, BMS, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Radioligand Therapy Drugs Industry Forecast” looks at past sales and reviews total world Radioligand Therapy Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Radioligand Therapy Drugs sales for 2026 through 2032. With Radioligand Therapy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radioligand Therapy Drugs industry.
This Insight Report provides a comprehensive analysis of the global Radioligand Therapy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Radioligand Therapy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Radioligand Therapy Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radioligand Therapy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radioligand Therapy Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Radioligand Therapy Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Lutetium 177
- Radium 223
- Acetium 225
- Others
- by Peptides
- Small Molecules
- Antibodies
- Others
- ?-emitters
- ?-emitters
- Others
- Prostate Cancer
- Liver Cancer
- Breast Cancer
- Lung Cancer
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- Bayer
- Progenics (Lantheus)
- Acrotech Biopharma Inc
- BMS
- AstraZeneca
- Eli Lilly
- Convergent Therapeutics
- Grand Pharmaceutical
- Bivision Pharmaceuticals
- Jiangsu Hengrui
- What is the 10-year outlook for the global Radioligand Therapy Drugs market?
- What factors are driving Radioligand Therapy Drugs market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Radioligand Therapy Drugs market opportunities vary by end market size?
- How does Radioligand Therapy Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Radioligand Therapy Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Radioligand Therapy Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Radioligand Therapy Drugs by Country/Region, 2021, 2025 & 2032
2.2 Radioligand Therapy Drugs Segment by Type
2.2.1 Lutetium
2.2.2 Radium
2.2.3 Acetium
2.2.4 Others
2.2.5 Radioligand Therapy Drugs Sales by Type
2.2.5.1 Global Radioligand Therapy Drugs Sales Market Share by Type (2021-2026)
2.2.5.2 Global Radioligand Therapy Drugs Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Radioligand Therapy Drugs Sale Price by Type (2021-2026)
2.3 Radioligand Therapy Drugs Segment by Targeted Ligands
2.3.1 by Peptides
2.3.2 Small Molecules
2.3.3 Antibodies
2.3.4 Others
2.3.5 Radioligand Therapy Drugs Sales by Targeted Ligands
2.3.5.1 Global Radioligand Therapy Drugs Sales Market Share by Targeted Ligands (2021-2026)
2.3.5.2 Global Radioligand Therapy Drugs Revenue and Market Share by Targeted Ligands (2021-2026)
2.3.5.3 Global Radioligand Therapy Drugs Sale Price by Targeted Ligands (2021-2026)
2.4 Radioligand Therapy Drugs Segment by Radionuclides
2.4.1 ?-emitters
2.4.2 ?-emitters
2.4.3 Others
2.4.4 Radioligand Therapy Drugs Sales by Radionuclides
2.4.4.1 Global Radioligand Therapy Drugs Sales Market Share by Radionuclides (2021-2026)
2.4.4.2 Global Radioligand Therapy Drugs Revenue and Market Share by Radionuclides (2021-2026)
2.4.4.3 Global Radioligand Therapy Drugs Sale Price by Radionuclides (2021-2026)
2.5 Radioligand Therapy Drugs Segment by Application
2.5.1 Prostate Cancer
2.5.2 Liver Cancer
2.5.3 Breast Cancer
2.5.4 Lung Cancer
2.5.5 Others
2.5.6 Radioligand Therapy Drugs Sales by Application
2.5.6.1 Global Radioligand Therapy Drugs Sale Market Share by Application (2021-2026)
2.5.6.2 Global Radioligand Therapy Drugs Revenue and Market Share by Application (2021-2026)
2.5.6.3 Global Radioligand Therapy Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Radioligand Therapy Drugs Breakdown Data by Company
3.1.1 Global Radioligand Therapy Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Radioligand Therapy Drugs Sales Market Share by Company (2021-2026)
3.2 Global Radioligand Therapy Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Radioligand Therapy Drugs Revenue by Company (2021-2026)
3.2.2 Global Radioligand Therapy Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Radioligand Therapy Drugs Sale Price by Company
3.4 Key Manufacturers Radioligand Therapy Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Radioligand Therapy Drugs Product Location Distribution
3.4.2 Players Radioligand Therapy Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RADIOLIGAND THERAPY DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Radioligand Therapy Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Radioligand Therapy Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Radioligand Therapy Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Radioligand Therapy Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Radioligand Therapy Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Radioligand Therapy Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Radioligand Therapy Drugs Sales Growth
4.4 APAC Radioligand Therapy Drugs Sales Growth
4.5 Europe Radioligand Therapy Drugs Sales Growth
4.6 Middle East & Africa Radioligand Therapy Drugs Sales Growth
5 AMERICAS
5.1 Americas Radioligand Therapy Drugs Sales by Country
5.1.1 Americas Radioligand Therapy Drugs Sales by Country (2021-2026)
5.1.2 Americas Radioligand Therapy Drugs Revenue by Country (2021-2026)
5.2 Americas Radioligand Therapy Drugs Sales by Type (2021-2026)
5.3 Americas Radioligand Therapy Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Radioligand Therapy Drugs Sales by Region
6.1.1 APAC Radioligand Therapy Drugs Sales by Region (2021-2026)
6.1.2 APAC Radioligand Therapy Drugs Revenue by Region (2021-2026)
6.2 APAC Radioligand Therapy Drugs Sales by Type (2021-2026)
6.3 APAC Radioligand Therapy Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Radioligand Therapy Drugs by Country
7.1.1 Europe Radioligand Therapy Drugs Sales by Country (2021-2026)
7.1.2 Europe Radioligand Therapy Drugs Revenue by Country (2021-2026)
7.2 Europe Radioligand Therapy Drugs Sales by Type (2021-2026)
7.3 Europe Radioligand Therapy Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Radioligand Therapy Drugs by Country
8.1.1 Middle East & Africa Radioligand Therapy Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Radioligand Therapy Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Radioligand Therapy Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Radioligand Therapy Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Radioligand Therapy Drugs
10.3 Manufacturing Process Analysis of Radioligand Therapy Drugs
10.4 Industry Chain Structure of Radioligand Therapy Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Radioligand Therapy Drugs Distributors
11.3 Radioligand Therapy Drugs Customer
12 WORLD FORECAST REVIEW FOR RADIOLIGAND THERAPY DRUGS BY GEOGRAPHIC REGION
12.1 Global Radioligand Therapy Drugs Market Size Forecast by Region
12.1.1 Global Radioligand Therapy Drugs Forecast by Region (2027-2032)
12.1.2 Global Radioligand Therapy Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Radioligand Therapy Drugs Forecast by Type (2027-2032)
12.7 Global Radioligand Therapy Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Radioligand Therapy Drugs Product Portfolios and Specifications
13.1.3 Novartis Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Radioligand Therapy Drugs Product Portfolios and Specifications
13.2.3 Bayer Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Progenics (Lantheus)
13.3.1 Progenics (Lantheus) Company Information
13.3.2 Progenics (Lantheus) Radioligand Therapy Drugs Product Portfolios and Specifications
13.3.3 Progenics (Lantheus) Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Progenics (Lantheus) Main Business Overview
13.3.5 Progenics (Lantheus) Latest Developments
13.4 Acrotech Biopharma Inc
13.4.1 Acrotech Biopharma Inc Company Information
13.4.2 Acrotech Biopharma Inc Radioligand Therapy Drugs Product Portfolios and Specifications
13.4.3 Acrotech Biopharma Inc Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Acrotech Biopharma Inc Main Business Overview
13.4.5 Acrotech Biopharma Inc Latest Developments
13.5 BMS
13.5.1 BMS Company Information
13.5.2 BMS Radioligand Therapy Drugs Product Portfolios and Specifications
13.5.3 BMS Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 BMS Main Business Overview
13.5.5 BMS Latest Developments
13.6 AstraZeneca
13.6.1 AstraZeneca Company Information
13.6.2 AstraZeneca Radioligand Therapy Drugs Product Portfolios and Specifications
13.6.3 AstraZeneca Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 AstraZeneca Main Business Overview
13.6.5 AstraZeneca Latest Developments
13.7 Eli Lilly
13.7.1 Eli Lilly Company Information
13.7.2 Eli Lilly Radioligand Therapy Drugs Product Portfolios and Specifications
13.7.3 Eli Lilly Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Eli Lilly Main Business Overview
13.7.5 Eli Lilly Latest Developments
13.8 Convergent Therapeutics
13.8.1 Convergent Therapeutics Company Information
13.8.2 Convergent Therapeutics Radioligand Therapy Drugs Product Portfolios and Specifications
13.8.3 Convergent Therapeutics Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Convergent Therapeutics Main Business Overview
13.8.5 Convergent Therapeutics Latest Developments
13.9 Grand Pharmaceutical
13.9.1 Grand Pharmaceutical Company Information
13.9.2 Grand Pharmaceutical Radioligand Therapy Drugs Product Portfolios and Specifications
13.9.3 Grand Pharmaceutical Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Grand Pharmaceutical Main Business Overview
13.9.5 Grand Pharmaceutical Latest Developments
13.10 Bivision Pharmaceuticals
13.10.1 Bivision Pharmaceuticals Company Information
13.10.2 Bivision Pharmaceuticals Radioligand Therapy Drugs Product Portfolios and Specifications
13.10.3 Bivision Pharmaceuticals Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Bivision Pharmaceuticals Main Business Overview
13.10.5 Bivision Pharmaceuticals Latest Developments
13.11 Jiangsu Hengrui
13.11.1 Jiangsu Hengrui Company Information
13.11.2 Jiangsu Hengrui Radioligand Therapy Drugs Product Portfolios and Specifications
13.11.3 Jiangsu Hengrui Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Jiangsu Hengrui Main Business Overview
13.11.5 Jiangsu Hengrui Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Radioligand Therapy Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Radioligand Therapy Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Radioligand Therapy Drugs by Country/Region, 2021, 2025 & 2032
2.2 Radioligand Therapy Drugs Segment by Type
2.2.1 Lutetium
2.2.2 Radium
2.2.3 Acetium
2.2.4 Others
2.2.5 Radioligand Therapy Drugs Sales by Type
2.2.5.1 Global Radioligand Therapy Drugs Sales Market Share by Type (2021-2026)
2.2.5.2 Global Radioligand Therapy Drugs Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Radioligand Therapy Drugs Sale Price by Type (2021-2026)
2.3 Radioligand Therapy Drugs Segment by Targeted Ligands
2.3.1 by Peptides
2.3.2 Small Molecules
2.3.3 Antibodies
2.3.4 Others
2.3.5 Radioligand Therapy Drugs Sales by Targeted Ligands
2.3.5.1 Global Radioligand Therapy Drugs Sales Market Share by Targeted Ligands (2021-2026)
2.3.5.2 Global Radioligand Therapy Drugs Revenue and Market Share by Targeted Ligands (2021-2026)
2.3.5.3 Global Radioligand Therapy Drugs Sale Price by Targeted Ligands (2021-2026)
2.4 Radioligand Therapy Drugs Segment by Radionuclides
2.4.1 ?-emitters
2.4.2 ?-emitters
2.4.3 Others
2.4.4 Radioligand Therapy Drugs Sales by Radionuclides
2.4.4.1 Global Radioligand Therapy Drugs Sales Market Share by Radionuclides (2021-2026)
2.4.4.2 Global Radioligand Therapy Drugs Revenue and Market Share by Radionuclides (2021-2026)
2.4.4.3 Global Radioligand Therapy Drugs Sale Price by Radionuclides (2021-2026)
2.5 Radioligand Therapy Drugs Segment by Application
2.5.1 Prostate Cancer
2.5.2 Liver Cancer
2.5.3 Breast Cancer
2.5.4 Lung Cancer
2.5.5 Others
2.5.6 Radioligand Therapy Drugs Sales by Application
2.5.6.1 Global Radioligand Therapy Drugs Sale Market Share by Application (2021-2026)
2.5.6.2 Global Radioligand Therapy Drugs Revenue and Market Share by Application (2021-2026)
2.5.6.3 Global Radioligand Therapy Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Radioligand Therapy Drugs Breakdown Data by Company
3.1.1 Global Radioligand Therapy Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Radioligand Therapy Drugs Sales Market Share by Company (2021-2026)
3.2 Global Radioligand Therapy Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Radioligand Therapy Drugs Revenue by Company (2021-2026)
3.2.2 Global Radioligand Therapy Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Radioligand Therapy Drugs Sale Price by Company
3.4 Key Manufacturers Radioligand Therapy Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Radioligand Therapy Drugs Product Location Distribution
3.4.2 Players Radioligand Therapy Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RADIOLIGAND THERAPY DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Radioligand Therapy Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Radioligand Therapy Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Radioligand Therapy Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Radioligand Therapy Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Radioligand Therapy Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Radioligand Therapy Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Radioligand Therapy Drugs Sales Growth
4.4 APAC Radioligand Therapy Drugs Sales Growth
4.5 Europe Radioligand Therapy Drugs Sales Growth
4.6 Middle East & Africa Radioligand Therapy Drugs Sales Growth
5 AMERICAS
5.1 Americas Radioligand Therapy Drugs Sales by Country
5.1.1 Americas Radioligand Therapy Drugs Sales by Country (2021-2026)
5.1.2 Americas Radioligand Therapy Drugs Revenue by Country (2021-2026)
5.2 Americas Radioligand Therapy Drugs Sales by Type (2021-2026)
5.3 Americas Radioligand Therapy Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Radioligand Therapy Drugs Sales by Region
6.1.1 APAC Radioligand Therapy Drugs Sales by Region (2021-2026)
6.1.2 APAC Radioligand Therapy Drugs Revenue by Region (2021-2026)
6.2 APAC Radioligand Therapy Drugs Sales by Type (2021-2026)
6.3 APAC Radioligand Therapy Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Radioligand Therapy Drugs by Country
7.1.1 Europe Radioligand Therapy Drugs Sales by Country (2021-2026)
7.1.2 Europe Radioligand Therapy Drugs Revenue by Country (2021-2026)
7.2 Europe Radioligand Therapy Drugs Sales by Type (2021-2026)
7.3 Europe Radioligand Therapy Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Radioligand Therapy Drugs by Country
8.1.1 Middle East & Africa Radioligand Therapy Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Radioligand Therapy Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Radioligand Therapy Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Radioligand Therapy Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Radioligand Therapy Drugs
10.3 Manufacturing Process Analysis of Radioligand Therapy Drugs
10.4 Industry Chain Structure of Radioligand Therapy Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Radioligand Therapy Drugs Distributors
11.3 Radioligand Therapy Drugs Customer
12 WORLD FORECAST REVIEW FOR RADIOLIGAND THERAPY DRUGS BY GEOGRAPHIC REGION
12.1 Global Radioligand Therapy Drugs Market Size Forecast by Region
12.1.1 Global Radioligand Therapy Drugs Forecast by Region (2027-2032)
12.1.2 Global Radioligand Therapy Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Radioligand Therapy Drugs Forecast by Type (2027-2032)
12.7 Global Radioligand Therapy Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Radioligand Therapy Drugs Product Portfolios and Specifications
13.1.3 Novartis Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Radioligand Therapy Drugs Product Portfolios and Specifications
13.2.3 Bayer Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Progenics (Lantheus)
13.3.1 Progenics (Lantheus) Company Information
13.3.2 Progenics (Lantheus) Radioligand Therapy Drugs Product Portfolios and Specifications
13.3.3 Progenics (Lantheus) Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Progenics (Lantheus) Main Business Overview
13.3.5 Progenics (Lantheus) Latest Developments
13.4 Acrotech Biopharma Inc
13.4.1 Acrotech Biopharma Inc Company Information
13.4.2 Acrotech Biopharma Inc Radioligand Therapy Drugs Product Portfolios and Specifications
13.4.3 Acrotech Biopharma Inc Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Acrotech Biopharma Inc Main Business Overview
13.4.5 Acrotech Biopharma Inc Latest Developments
13.5 BMS
13.5.1 BMS Company Information
13.5.2 BMS Radioligand Therapy Drugs Product Portfolios and Specifications
13.5.3 BMS Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 BMS Main Business Overview
13.5.5 BMS Latest Developments
13.6 AstraZeneca
13.6.1 AstraZeneca Company Information
13.6.2 AstraZeneca Radioligand Therapy Drugs Product Portfolios and Specifications
13.6.3 AstraZeneca Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 AstraZeneca Main Business Overview
13.6.5 AstraZeneca Latest Developments
13.7 Eli Lilly
13.7.1 Eli Lilly Company Information
13.7.2 Eli Lilly Radioligand Therapy Drugs Product Portfolios and Specifications
13.7.3 Eli Lilly Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Eli Lilly Main Business Overview
13.7.5 Eli Lilly Latest Developments
13.8 Convergent Therapeutics
13.8.1 Convergent Therapeutics Company Information
13.8.2 Convergent Therapeutics Radioligand Therapy Drugs Product Portfolios and Specifications
13.8.3 Convergent Therapeutics Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Convergent Therapeutics Main Business Overview
13.8.5 Convergent Therapeutics Latest Developments
13.9 Grand Pharmaceutical
13.9.1 Grand Pharmaceutical Company Information
13.9.2 Grand Pharmaceutical Radioligand Therapy Drugs Product Portfolios and Specifications
13.9.3 Grand Pharmaceutical Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Grand Pharmaceutical Main Business Overview
13.9.5 Grand Pharmaceutical Latest Developments
13.10 Bivision Pharmaceuticals
13.10.1 Bivision Pharmaceuticals Company Information
13.10.2 Bivision Pharmaceuticals Radioligand Therapy Drugs Product Portfolios and Specifications
13.10.3 Bivision Pharmaceuticals Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Bivision Pharmaceuticals Main Business Overview
13.10.5 Bivision Pharmaceuticals Latest Developments
13.11 Jiangsu Hengrui
13.11.1 Jiangsu Hengrui Company Information
13.11.2 Jiangsu Hengrui Radioligand Therapy Drugs Product Portfolios and Specifications
13.11.3 Jiangsu Hengrui Radioligand Therapy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Jiangsu Hengrui Main Business Overview
13.11.5 Jiangsu Hengrui Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Radioligand Therapy Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Radioligand Therapy Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Lutetium 177
Table 4. Major Players of Radium 223
Table 5. Major Players of Acetium 225
Table 6. Major Players of Others
Table 7. Global Radioligand Therapy Drugs Sales by Type (2021-2026) & (K Units)
Table 8. Global Radioligand Therapy Drugs Sales Market Share by Type (2021-2026)
Table 9. Global Radioligand Therapy Drugs Revenue by Type (2021-2026) & ($ million)
Table 10. Global Radioligand Therapy Drugs Revenue Market Share by Type (2021-2026)
Table 11. Global Radioligand Therapy Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Major Players of by Peptides
Table 13. Major Players of Small Molecules
Table 14. Major Players of Antibodies
Table 15. Major Players of Others
Table 16. Global Radioligand Therapy Drugs Sales by Targeted Ligands (2021-2026) & (K Units)
Table 17. Global Radioligand Therapy Drugs Sales Market Share by Targeted Ligands (2021-2026)
Table 18. Global Radioligand Therapy Drugs Revenue by Targeted Ligands (2021-2026) & ($ million)
Table 19. Global Radioligand Therapy Drugs Revenue Market Share by Targeted Ligands (2021-2026)
Table 20. Global Radioligand Therapy Drugs Sale Price by Targeted Ligands (2021-2026) & (US$/Unit)
Table 21. Major Players of ?-emitters
Table 22. Major Players of ?-emitters
Table 23. Major Players of Others
Table 24. Global Radioligand Therapy Drugs Sales by Radionuclides (2021-2026) & (K Units)
Table 25. Global Radioligand Therapy Drugs Sales Market Share by Radionuclides (2021-2026)
Table 26. Global Radioligand Therapy Drugs Revenue by Radionuclides (2021-2026) & ($ million)
Table 27. Global Radioligand Therapy Drugs Revenue Market Share by Radionuclides (2021-2026)
Table 28. Global Radioligand Therapy Drugs Sale Price by Radionuclides (2021-2026) & (US$/Unit)
Table 29. Global Radioligand Therapy Drugs Sale by Application (2021-2026) & (K Units)
Table 30. Global Radioligand Therapy Drugs Sale Market Share by Application (2021-2026)
Table 31. Global Radioligand Therapy Drugs Revenue by Application (2021-2026) & ($ million)
Table 32. Global Radioligand Therapy Drugs Revenue Market Share by Application (2021-2026)
Table 33. Global Radioligand Therapy Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 34. Global Radioligand Therapy Drugs Sales by Company (2021-2026) & (K Units)
Table 35. Global Radioligand Therapy Drugs Sales Market Share by Company (2021-2026)
Table 36. Global Radioligand Therapy Drugs Revenue by Company (2021-2026) & ($ millions)
Table 37. Global Radioligand Therapy Drugs Revenue Market Share by Company (2021-2026)
Table 38. Global Radioligand Therapy Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 39. Key Manufacturers Radioligand Therapy Drugs Producing Area Distribution and Sales Area
Table 40. Players Radioligand Therapy Drugs Products Offered
Table 41. Radioligand Therapy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 42. New Products and Potential Entrants
Table 43. Market M&A Activity & Strategy
Table 44. Global Radioligand Therapy Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 45. Global Radioligand Therapy Drugs Sales Market Share Geographic Region (2021-2026)
Table 46. Global Radioligand Therapy Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 47. Global Radioligand Therapy Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 48. Global Radioligand Therapy Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 49. Global Radioligand Therapy Drugs Sales Market Share by Country/Region (2021-2026)
Table 50. Global Radioligand Therapy Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 51. Global Radioligand Therapy Drugs Revenue Market Share by Country/Region (2021-2026)
Table 52. Americas Radioligand Therapy Drugs Sales by Country (2021-2026) & (K Units)
Table 53. Americas Radioligand Therapy Drugs Sales Market Share by Country (2021-2026)
Table 54. Americas Radioligand Therapy Drugs Revenue by Country (2021-2026) & ($ millions)
Table 55. Americas Radioligand Therapy Drugs Sales by Type (2021-2026) & (K Units)
Table 56. Americas Radioligand Therapy Drugs Sales by Application (2021-2026) & (K Units)
Table 57. APAC Radioligand Therapy Drugs Sales by Region (2021-2026) & (K Units)
Table 58. APAC Radioligand Therapy Drugs Sales Market Share by Region (2021-2026)
Table 59. APAC Radioligand Therapy Drugs Revenue by Region (2021-2026) & ($ millions)
Table 60. APAC Radioligand Therapy Drugs Sales by Type (2021-2026) & (K Units)
Table 61. APAC Radioligand Therapy Drugs Sales by Application (2021-2026) & (K Units)
Table 62. Europe Radioligand Therapy Drugs Sales by Country (2021-2026) & (K Units)
Table 63. Europe Radioligand Therapy Drugs Revenue by Country (2021-2026) & ($ millions)
Table 64. Europe Radioligand Therapy Drugs Sales by Type (2021-2026) & (K Units)
Table 65. Europe Radioligand Therapy Drugs Sales by Application (2021-2026) & (K Units)
Table 66. Middle East & Africa Radioligand Therapy Drugs Sales by Country (2021-2026) & (K Units)
Table 67. Middle East & Africa Radioligand Therapy Drugs Revenue Market Share by Country (2021-2026)
Table 68. Middle East & Africa Radioligand Therapy Drugs Sales by Type (2021-2026) & (K Units)
Table 69. Middle East & Africa Radioligand Therapy Drugs Sales by Application (2021-2026) & (K Units)
Table 70. Key Market Drivers & Growth Opportunities of Radioligand Therapy Drugs
Table 71. Key Market Challenges & Risks of Radioligand Therapy Drugs
Table 72. Key Industry Trends of Radioligand Therapy Drugs
Table 73. Radioligand Therapy Drugs Raw Material
Table 74. Key Suppliers of Raw Materials
Table 75. Radioligand Therapy Drugs Distributors List
Table 76. Radioligand Therapy Drugs Customer List
Table 77. Global Radioligand Therapy Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 78. Global Radioligand Therapy Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Americas Radioligand Therapy Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 80. Americas Radioligand Therapy Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. APAC Radioligand Therapy Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 82. APAC Radioligand Therapy Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 83. Europe Radioligand Therapy Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 84. Europe Radioligand Therapy Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Middle East & Africa Radioligand Therapy Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 86. Middle East & Africa Radioligand Therapy Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Global Radioligand Therapy Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 88. Global Radioligand Therapy Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 89. Global Radioligand Therapy Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 90. Global Radioligand Therapy Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 91. Novartis Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Novartis Radioligand Therapy Drugs Product Portfolios and Specifications
Table 93. Novartis Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Novartis Main Business
Table 95. Novartis Latest Developments
Table 96. Bayer Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. Bayer Radioligand Therapy Drugs Product Portfolios and Specifications
Table 98. Bayer Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Bayer Main Business
Table 100. Bayer Latest Developments
Table 101. Progenics (Lantheus) Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. Progenics (Lantheus) Radioligand Therapy Drugs Product Portfolios and Specifications
Table 103. Progenics (Lantheus) Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Progenics (Lantheus) Main Business
Table 105. Progenics (Lantheus) Latest Developments
Table 106. Acrotech Biopharma Inc Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. Acrotech Biopharma Inc Radioligand Therapy Drugs Product Portfolios and Specifications
Table 108. Acrotech Biopharma Inc Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Acrotech Biopharma Inc Main Business
Table 110. Acrotech Biopharma Inc Latest Developments
Table 111. BMS Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 112. BMS Radioligand Therapy Drugs Product Portfolios and Specifications
Table 113. BMS Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. BMS Main Business
Table 115. BMS Latest Developments
Table 116. AstraZeneca Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. AstraZeneca Radioligand Therapy Drugs Product Portfolios and Specifications
Table 118. AstraZeneca Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. AstraZeneca Main Business
Table 120. AstraZeneca Latest Developments
Table 121. Eli Lilly Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 122. Eli Lilly Radioligand Therapy Drugs Product Portfolios and Specifications
Table 123. Eli Lilly Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. Eli Lilly Main Business
Table 125. Eli Lilly Latest Developments
Table 126. Convergent Therapeutics Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 127. Convergent Therapeutics Radioligand Therapy Drugs Product Portfolios and Specifications
Table 128. Convergent Therapeutics Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. Convergent Therapeutics Main Business
Table 130. Convergent Therapeutics Latest Developments
Table 131. Grand Pharmaceutical Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 132. Grand Pharmaceutical Radioligand Therapy Drugs Product Portfolios and Specifications
Table 133. Grand Pharmaceutical Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Grand Pharmaceutical Main Business
Table 135. Grand Pharmaceutical Latest Developments
Table 136. Bivision Pharmaceuticals Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 137. Bivision Pharmaceuticals Radioligand Therapy Drugs Product Portfolios and Specifications
Table 138. Bivision Pharmaceuticals Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. Bivision Pharmaceuticals Main Business
Table 140. Bivision Pharmaceuticals Latest Developments
Table 141. Jiangsu Hengrui Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 142. Jiangsu Hengrui Radioligand Therapy Drugs Product Portfolios and Specifications
Table 143. Jiangsu Hengrui Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 144. Jiangsu Hengrui Main Business
Table 145. Jiangsu Hengrui Latest Developments
Table 1. Radioligand Therapy Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Radioligand Therapy Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Lutetium 177
Table 4. Major Players of Radium 223
Table 5. Major Players of Acetium 225
Table 6. Major Players of Others
Table 7. Global Radioligand Therapy Drugs Sales by Type (2021-2026) & (K Units)
Table 8. Global Radioligand Therapy Drugs Sales Market Share by Type (2021-2026)
Table 9. Global Radioligand Therapy Drugs Revenue by Type (2021-2026) & ($ million)
Table 10. Global Radioligand Therapy Drugs Revenue Market Share by Type (2021-2026)
Table 11. Global Radioligand Therapy Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Major Players of by Peptides
Table 13. Major Players of Small Molecules
Table 14. Major Players of Antibodies
Table 15. Major Players of Others
Table 16. Global Radioligand Therapy Drugs Sales by Targeted Ligands (2021-2026) & (K Units)
Table 17. Global Radioligand Therapy Drugs Sales Market Share by Targeted Ligands (2021-2026)
Table 18. Global Radioligand Therapy Drugs Revenue by Targeted Ligands (2021-2026) & ($ million)
Table 19. Global Radioligand Therapy Drugs Revenue Market Share by Targeted Ligands (2021-2026)
Table 20. Global Radioligand Therapy Drugs Sale Price by Targeted Ligands (2021-2026) & (US$/Unit)
Table 21. Major Players of ?-emitters
Table 22. Major Players of ?-emitters
Table 23. Major Players of Others
Table 24. Global Radioligand Therapy Drugs Sales by Radionuclides (2021-2026) & (K Units)
Table 25. Global Radioligand Therapy Drugs Sales Market Share by Radionuclides (2021-2026)
Table 26. Global Radioligand Therapy Drugs Revenue by Radionuclides (2021-2026) & ($ million)
Table 27. Global Radioligand Therapy Drugs Revenue Market Share by Radionuclides (2021-2026)
Table 28. Global Radioligand Therapy Drugs Sale Price by Radionuclides (2021-2026) & (US$/Unit)
Table 29. Global Radioligand Therapy Drugs Sale by Application (2021-2026) & (K Units)
Table 30. Global Radioligand Therapy Drugs Sale Market Share by Application (2021-2026)
Table 31. Global Radioligand Therapy Drugs Revenue by Application (2021-2026) & ($ million)
Table 32. Global Radioligand Therapy Drugs Revenue Market Share by Application (2021-2026)
Table 33. Global Radioligand Therapy Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 34. Global Radioligand Therapy Drugs Sales by Company (2021-2026) & (K Units)
Table 35. Global Radioligand Therapy Drugs Sales Market Share by Company (2021-2026)
Table 36. Global Radioligand Therapy Drugs Revenue by Company (2021-2026) & ($ millions)
Table 37. Global Radioligand Therapy Drugs Revenue Market Share by Company (2021-2026)
Table 38. Global Radioligand Therapy Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 39. Key Manufacturers Radioligand Therapy Drugs Producing Area Distribution and Sales Area
Table 40. Players Radioligand Therapy Drugs Products Offered
Table 41. Radioligand Therapy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 42. New Products and Potential Entrants
Table 43. Market M&A Activity & Strategy
Table 44. Global Radioligand Therapy Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 45. Global Radioligand Therapy Drugs Sales Market Share Geographic Region (2021-2026)
Table 46. Global Radioligand Therapy Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 47. Global Radioligand Therapy Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 48. Global Radioligand Therapy Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 49. Global Radioligand Therapy Drugs Sales Market Share by Country/Region (2021-2026)
Table 50. Global Radioligand Therapy Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 51. Global Radioligand Therapy Drugs Revenue Market Share by Country/Region (2021-2026)
Table 52. Americas Radioligand Therapy Drugs Sales by Country (2021-2026) & (K Units)
Table 53. Americas Radioligand Therapy Drugs Sales Market Share by Country (2021-2026)
Table 54. Americas Radioligand Therapy Drugs Revenue by Country (2021-2026) & ($ millions)
Table 55. Americas Radioligand Therapy Drugs Sales by Type (2021-2026) & (K Units)
Table 56. Americas Radioligand Therapy Drugs Sales by Application (2021-2026) & (K Units)
Table 57. APAC Radioligand Therapy Drugs Sales by Region (2021-2026) & (K Units)
Table 58. APAC Radioligand Therapy Drugs Sales Market Share by Region (2021-2026)
Table 59. APAC Radioligand Therapy Drugs Revenue by Region (2021-2026) & ($ millions)
Table 60. APAC Radioligand Therapy Drugs Sales by Type (2021-2026) & (K Units)
Table 61. APAC Radioligand Therapy Drugs Sales by Application (2021-2026) & (K Units)
Table 62. Europe Radioligand Therapy Drugs Sales by Country (2021-2026) & (K Units)
Table 63. Europe Radioligand Therapy Drugs Revenue by Country (2021-2026) & ($ millions)
Table 64. Europe Radioligand Therapy Drugs Sales by Type (2021-2026) & (K Units)
Table 65. Europe Radioligand Therapy Drugs Sales by Application (2021-2026) & (K Units)
Table 66. Middle East & Africa Radioligand Therapy Drugs Sales by Country (2021-2026) & (K Units)
Table 67. Middle East & Africa Radioligand Therapy Drugs Revenue Market Share by Country (2021-2026)
Table 68. Middle East & Africa Radioligand Therapy Drugs Sales by Type (2021-2026) & (K Units)
Table 69. Middle East & Africa Radioligand Therapy Drugs Sales by Application (2021-2026) & (K Units)
Table 70. Key Market Drivers & Growth Opportunities of Radioligand Therapy Drugs
Table 71. Key Market Challenges & Risks of Radioligand Therapy Drugs
Table 72. Key Industry Trends of Radioligand Therapy Drugs
Table 73. Radioligand Therapy Drugs Raw Material
Table 74. Key Suppliers of Raw Materials
Table 75. Radioligand Therapy Drugs Distributors List
Table 76. Radioligand Therapy Drugs Customer List
Table 77. Global Radioligand Therapy Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 78. Global Radioligand Therapy Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Americas Radioligand Therapy Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 80. Americas Radioligand Therapy Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. APAC Radioligand Therapy Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 82. APAC Radioligand Therapy Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 83. Europe Radioligand Therapy Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 84. Europe Radioligand Therapy Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Middle East & Africa Radioligand Therapy Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 86. Middle East & Africa Radioligand Therapy Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Global Radioligand Therapy Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 88. Global Radioligand Therapy Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 89. Global Radioligand Therapy Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 90. Global Radioligand Therapy Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 91. Novartis Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Novartis Radioligand Therapy Drugs Product Portfolios and Specifications
Table 93. Novartis Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Novartis Main Business
Table 95. Novartis Latest Developments
Table 96. Bayer Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. Bayer Radioligand Therapy Drugs Product Portfolios and Specifications
Table 98. Bayer Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Bayer Main Business
Table 100. Bayer Latest Developments
Table 101. Progenics (Lantheus) Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. Progenics (Lantheus) Radioligand Therapy Drugs Product Portfolios and Specifications
Table 103. Progenics (Lantheus) Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Progenics (Lantheus) Main Business
Table 105. Progenics (Lantheus) Latest Developments
Table 106. Acrotech Biopharma Inc Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. Acrotech Biopharma Inc Radioligand Therapy Drugs Product Portfolios and Specifications
Table 108. Acrotech Biopharma Inc Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Acrotech Biopharma Inc Main Business
Table 110. Acrotech Biopharma Inc Latest Developments
Table 111. BMS Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 112. BMS Radioligand Therapy Drugs Product Portfolios and Specifications
Table 113. BMS Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. BMS Main Business
Table 115. BMS Latest Developments
Table 116. AstraZeneca Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. AstraZeneca Radioligand Therapy Drugs Product Portfolios and Specifications
Table 118. AstraZeneca Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. AstraZeneca Main Business
Table 120. AstraZeneca Latest Developments
Table 121. Eli Lilly Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 122. Eli Lilly Radioligand Therapy Drugs Product Portfolios and Specifications
Table 123. Eli Lilly Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. Eli Lilly Main Business
Table 125. Eli Lilly Latest Developments
Table 126. Convergent Therapeutics Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 127. Convergent Therapeutics Radioligand Therapy Drugs Product Portfolios and Specifications
Table 128. Convergent Therapeutics Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. Convergent Therapeutics Main Business
Table 130. Convergent Therapeutics Latest Developments
Table 131. Grand Pharmaceutical Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 132. Grand Pharmaceutical Radioligand Therapy Drugs Product Portfolios and Specifications
Table 133. Grand Pharmaceutical Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Grand Pharmaceutical Main Business
Table 135. Grand Pharmaceutical Latest Developments
Table 136. Bivision Pharmaceuticals Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 137. Bivision Pharmaceuticals Radioligand Therapy Drugs Product Portfolios and Specifications
Table 138. Bivision Pharmaceuticals Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. Bivision Pharmaceuticals Main Business
Table 140. Bivision Pharmaceuticals Latest Developments
Table 141. Jiangsu Hengrui Basic Information, Radioligand Therapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 142. Jiangsu Hengrui Radioligand Therapy Drugs Product Portfolios and Specifications
Table 143. Jiangsu Hengrui Radioligand Therapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 144. Jiangsu Hengrui Main Business
Table 145. Jiangsu Hengrui Latest Developments
LIST OF FIGURES
Figure 1. Picture of Radioligand Therapy Drugs
Figure 2. Radioligand Therapy Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Radioligand Therapy Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Radioligand Therapy Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Radioligand Therapy Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Radioligand Therapy Drugs Sales Market Share by Country/Region (2025)
Figure 10. Radioligand Therapy Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Lutetium 177
Figure 12. Product Picture of Radium 223
Figure 13. Product Picture of Acetium 225
Figure 14. Product Picture of Others
Figure 15. Global Radioligand Therapy Drugs Sales Market Share by Type in 2026
Figure 16. Global Radioligand Therapy Drugs Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of by Peptides
Figure 18. Product Picture of Small Molecules
Figure 19. Product Picture of Antibodies
Figure 20. Product Picture of Others
Figure 21. Global Radioligand Therapy Drugs Sales Market Share by Targeted Ligands in 2026
Figure 22. Global Radioligand Therapy Drugs Revenue Market Share by Targeted Ligands (2021-2026)
Figure 23. Product Picture of ?-emitters
Figure 24. Product Picture of ?-emitters
Figure 25. Product Picture of Others
Figure 26. Global Radioligand Therapy Drugs Sales Market Share by Radionuclides in 2026
Figure 27. Global Radioligand Therapy Drugs Revenue Market Share by Radionuclides (2021-2026)
Figure 28. Radioligand Therapy Drugs Consumed in Prostate Cancer
Figure 29. Global Radioligand Therapy Drugs Market: Prostate Cancer (2021-2026) & (K Units)
Figure 30. Radioligand Therapy Drugs Consumed in Liver Cancer
Figure 31. Global Radioligand Therapy Drugs Market: Liver Cancer (2021-2026) & (K Units)
Figure 32. Radioligand Therapy Drugs Consumed in Breast Cancer
Figure 33. Global Radioligand Therapy Drugs Market: Breast Cancer (2021-2026) & (K Units)
Figure 34. Radioligand Therapy Drugs Consumed in Lung Cancer
Figure 35. Global Radioligand Therapy Drugs Market: Lung Cancer (2021-2026) & (K Units)
Figure 36. Radioligand Therapy Drugs Consumed in Others
Figure 37. Global Radioligand Therapy Drugs Market: Others (2021-2026) & (K Units)
Figure 38. Global Radioligand Therapy Drugs Sale Market Share by Application (2025)
Figure 39. Global Radioligand Therapy Drugs Revenue Market Share by Application in 2026
Figure 40. Radioligand Therapy Drugs Sales by Company in 2026 (K Units)
Figure 41. Global Radioligand Therapy Drugs Sales Market Share by Company in 2026
Figure 42. Radioligand Therapy Drugs Revenue by Company in 2026 ($ millions)
Figure 43. Global Radioligand Therapy Drugs Revenue Market Share by Company in 2026
Figure 44. Global Radioligand Therapy Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 45. Global Radioligand Therapy Drugs Revenue Market Share by Geographic Region in 2026
Figure 46. Americas Radioligand Therapy Drugs Sales 2021-2026 (K Units)
Figure 47. Americas Radioligand Therapy Drugs Revenue 2021-2026 ($ millions)
Figure 48. APAC Radioligand Therapy Drugs Sales 2021-2026 (K Units)
Figure 49. APAC Radioligand Therapy Drugs Revenue 2021-2026 ($ millions)
Figure 50. Europe Radioligand Therapy Drugs Sales 2021-2026 (K Units)
Figure 51. Europe Radioligand Therapy Drugs Revenue 2021-2026 ($ millions)
Figure 52. Middle East & Africa Radioligand Therapy Drugs Sales 2021-2026 (K Units)
Figure 53. Middle East & Africa Radioligand Therapy Drugs Revenue 2021-2026 ($ millions)
Figure 54. Americas Radioligand Therapy Drugs Sales Market Share by Country in 2026
Figure 55. Americas Radioligand Therapy Drugs Revenue Market Share by Country (2021-2026)
Figure 56. Americas Radioligand Therapy Drugs Sales Market Share by Type (2021-2026)
Figure 57. Americas Radioligand Therapy Drugs Sales Market Share by Application (2021-2026)
Figure 58. United States Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 59. Canada Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 60. Mexico Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 61. Brazil Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 62. APAC Radioligand Therapy Drugs Sales Market Share by Region in 2026
Figure 63. APAC Radioligand Therapy Drugs Revenue Market Share by Region (2021-2026)
Figure 64. APAC Radioligand Therapy Drugs Sales Market Share by Type (2021-2026)
Figure 65. APAC Radioligand Therapy Drugs Sales Market Share by Application (2021-2026)
Figure 66. China Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. Japan Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 68. South Korea Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 69. Southeast Asia Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 70. India Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. Australia Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. China Taiwan Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Europe Radioligand Therapy Drugs Sales Market Share by Country in 2026
Figure 74. Europe Radioligand Therapy Drugs Revenue Market Share by Country (2021-2026)
Figure 75. Europe Radioligand Therapy Drugs Sales Market Share by Type (2021-2026)
Figure 76. Europe Radioligand Therapy Drugs Sales Market Share by Application (2021-2026)
Figure 77. Germany Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 78. France Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 79. UK Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 80. Italy Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 81. Russia Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 82. Middle East & Africa Radioligand Therapy Drugs Sales Market Share by Country (2021-2026)
Figure 83. Middle East & Africa Radioligand Therapy Drugs Sales Market Share by Type (2021-2026)
Figure 84. Middle East & Africa Radioligand Therapy Drugs Sales Market Share by Application (2021-2026)
Figure 85. Egypt Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 86. South Africa Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 87. Israel Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 88. Turkey Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 89. GCC Countries Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 90. Manufacturing Cost Structure Analysis of Radioligand Therapy Drugs in 2026
Figure 91. Manufacturing Process Analysis of Radioligand Therapy Drugs
Figure 92. Industry Chain Structure of Radioligand Therapy Drugs
Figure 93. Channels of Distribution
Figure 94. Global Radioligand Therapy Drugs Sales Market Forecast by Region (2027-2032)
Figure 95. Global Radioligand Therapy Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 96. Global Radioligand Therapy Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 97. Global Radioligand Therapy Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 98. Global Radioligand Therapy Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 99. Global Radioligand Therapy Drugs Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Radioligand Therapy Drugs
Figure 2. Radioligand Therapy Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Radioligand Therapy Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Radioligand Therapy Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Radioligand Therapy Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Radioligand Therapy Drugs Sales Market Share by Country/Region (2025)
Figure 10. Radioligand Therapy Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Lutetium 177
Figure 12. Product Picture of Radium 223
Figure 13. Product Picture of Acetium 225
Figure 14. Product Picture of Others
Figure 15. Global Radioligand Therapy Drugs Sales Market Share by Type in 2026
Figure 16. Global Radioligand Therapy Drugs Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of by Peptides
Figure 18. Product Picture of Small Molecules
Figure 19. Product Picture of Antibodies
Figure 20. Product Picture of Others
Figure 21. Global Radioligand Therapy Drugs Sales Market Share by Targeted Ligands in 2026
Figure 22. Global Radioligand Therapy Drugs Revenue Market Share by Targeted Ligands (2021-2026)
Figure 23. Product Picture of ?-emitters
Figure 24. Product Picture of ?-emitters
Figure 25. Product Picture of Others
Figure 26. Global Radioligand Therapy Drugs Sales Market Share by Radionuclides in 2026
Figure 27. Global Radioligand Therapy Drugs Revenue Market Share by Radionuclides (2021-2026)
Figure 28. Radioligand Therapy Drugs Consumed in Prostate Cancer
Figure 29. Global Radioligand Therapy Drugs Market: Prostate Cancer (2021-2026) & (K Units)
Figure 30. Radioligand Therapy Drugs Consumed in Liver Cancer
Figure 31. Global Radioligand Therapy Drugs Market: Liver Cancer (2021-2026) & (K Units)
Figure 32. Radioligand Therapy Drugs Consumed in Breast Cancer
Figure 33. Global Radioligand Therapy Drugs Market: Breast Cancer (2021-2026) & (K Units)
Figure 34. Radioligand Therapy Drugs Consumed in Lung Cancer
Figure 35. Global Radioligand Therapy Drugs Market: Lung Cancer (2021-2026) & (K Units)
Figure 36. Radioligand Therapy Drugs Consumed in Others
Figure 37. Global Radioligand Therapy Drugs Market: Others (2021-2026) & (K Units)
Figure 38. Global Radioligand Therapy Drugs Sale Market Share by Application (2025)
Figure 39. Global Radioligand Therapy Drugs Revenue Market Share by Application in 2026
Figure 40. Radioligand Therapy Drugs Sales by Company in 2026 (K Units)
Figure 41. Global Radioligand Therapy Drugs Sales Market Share by Company in 2026
Figure 42. Radioligand Therapy Drugs Revenue by Company in 2026 ($ millions)
Figure 43. Global Radioligand Therapy Drugs Revenue Market Share by Company in 2026
Figure 44. Global Radioligand Therapy Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 45. Global Radioligand Therapy Drugs Revenue Market Share by Geographic Region in 2026
Figure 46. Americas Radioligand Therapy Drugs Sales 2021-2026 (K Units)
Figure 47. Americas Radioligand Therapy Drugs Revenue 2021-2026 ($ millions)
Figure 48. APAC Radioligand Therapy Drugs Sales 2021-2026 (K Units)
Figure 49. APAC Radioligand Therapy Drugs Revenue 2021-2026 ($ millions)
Figure 50. Europe Radioligand Therapy Drugs Sales 2021-2026 (K Units)
Figure 51. Europe Radioligand Therapy Drugs Revenue 2021-2026 ($ millions)
Figure 52. Middle East & Africa Radioligand Therapy Drugs Sales 2021-2026 (K Units)
Figure 53. Middle East & Africa Radioligand Therapy Drugs Revenue 2021-2026 ($ millions)
Figure 54. Americas Radioligand Therapy Drugs Sales Market Share by Country in 2026
Figure 55. Americas Radioligand Therapy Drugs Revenue Market Share by Country (2021-2026)
Figure 56. Americas Radioligand Therapy Drugs Sales Market Share by Type (2021-2026)
Figure 57. Americas Radioligand Therapy Drugs Sales Market Share by Application (2021-2026)
Figure 58. United States Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 59. Canada Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 60. Mexico Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 61. Brazil Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 62. APAC Radioligand Therapy Drugs Sales Market Share by Region in 2026
Figure 63. APAC Radioligand Therapy Drugs Revenue Market Share by Region (2021-2026)
Figure 64. APAC Radioligand Therapy Drugs Sales Market Share by Type (2021-2026)
Figure 65. APAC Radioligand Therapy Drugs Sales Market Share by Application (2021-2026)
Figure 66. China Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. Japan Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 68. South Korea Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 69. Southeast Asia Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 70. India Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. Australia Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. China Taiwan Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Europe Radioligand Therapy Drugs Sales Market Share by Country in 2026
Figure 74. Europe Radioligand Therapy Drugs Revenue Market Share by Country (2021-2026)
Figure 75. Europe Radioligand Therapy Drugs Sales Market Share by Type (2021-2026)
Figure 76. Europe Radioligand Therapy Drugs Sales Market Share by Application (2021-2026)
Figure 77. Germany Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 78. France Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 79. UK Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 80. Italy Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 81. Russia Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 82. Middle East & Africa Radioligand Therapy Drugs Sales Market Share by Country (2021-2026)
Figure 83. Middle East & Africa Radioligand Therapy Drugs Sales Market Share by Type (2021-2026)
Figure 84. Middle East & Africa Radioligand Therapy Drugs Sales Market Share by Application (2021-2026)
Figure 85. Egypt Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 86. South Africa Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 87. Israel Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 88. Turkey Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 89. GCC Countries Radioligand Therapy Drugs Revenue Growth 2021-2026 ($ millions)
Figure 90. Manufacturing Cost Structure Analysis of Radioligand Therapy Drugs in 2026
Figure 91. Manufacturing Process Analysis of Radioligand Therapy Drugs
Figure 92. Industry Chain Structure of Radioligand Therapy Drugs
Figure 93. Channels of Distribution
Figure 94. Global Radioligand Therapy Drugs Sales Market Forecast by Region (2027-2032)
Figure 95. Global Radioligand Therapy Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 96. Global Radioligand Therapy Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 97. Global Radioligand Therapy Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 98. Global Radioligand Therapy Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 99. Global Radioligand Therapy Drugs Revenue Market Share Forecast by Application (2027-2032)
